Welcome to our dedicated page for EyePoint Pharmaceuticals news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint Pharmaceuticals stock.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts. The company is committed to developing and commercializing ophthalmic products aimed at treating serious retinal diseases. EyePoint leverages its proprietary Durasert® technology, a sustained intraocular drug delivery system, to create treatments that can provide continuous therapeutic effects for extended periods.
EyePoint Pharmaceuticals has made significant strides in the field of retinal disease treatments. Its lead product candidate, DURAVYU™ (previously known as EYP-1901), is an investigational treatment for VEGF-mediated retinal diseases. This product combines vorolanib, a selective tyrosine kinase inhibitor, with the Durasert® technology to offer sustained delivery and improved patient outcomes. DURAVYU™ is currently undergoing clinical trials for conditions such as wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR).
The company also has several other promising candidates in its pipeline, including EYP-2301, a TIE-2 agonist, and razuprotafib, formulated with Durasert® technology to potentially enhance treatment outcomes for serious retinal diseases.
EyePoint’s innovative approach extends beyond product development to strategic partnerships and collaborations. The company has secured exclusive licenses for vorolanib from Equinox Sciences for all ophthalmic uses outside of China, Macao, Hong Kong, and Taiwan. Additionally, EyePoint has FDA-approved products such as RETISERT® and YUTIQ® that are based on its proprietary drug delivery technology.
Financially, EyePoint Pharmaceuticals has shown a solid performance with total net revenue of $46.0 million for the year ended December 31, 2023, compared to $41.4 million for the previous year. This growth is driven primarily by revenues from royalties and collaborations. The company has also strengthened its financial position with $331.1 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
EyePoint is dedicated to driving innovation in ophthalmology and improving the quality of life for patients with serious eye conditions. With a focus on advancing its robust pipeline through clinical development, EyePoint Pharmaceuticals continues to make headway in addressing unmet medical needs in retinal diseases.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that CEO Nancy Lurker will present at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021. The presentation will be accessible for on-demand viewing starting at 9:00 a.m. ET on the company’s website, with a replay available for 90 days. EyePoint focuses on innovative therapeutics for serious eye disorders, leveraging its Durasert® technology. The company’s current portfolio includes YUTIQ® and DEXYCU®, targeting chronic non-infectious uveitis and postoperative inflammation, respectively.
EyePoint Pharmaceuticals (EYPT) reported a substantial 136% increase in net product revenues to $8.7 million for Q2 2021 compared to $3.7 million in Q2 2020. The company's Phase 1 DAVIO trial for EYP-1901, a treatment for wet AMD, has shown positive 30-day safety data, with no serious adverse events reported. Customer demand for DEXYCU and YUTIQ surged, with DEXYCU achieving a record of 10,900 units sold, a 404% increase year-over-year. However, operating expenses rose to $20 million, contributing to a net loss of $10 million for the quarter.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has formed an Executive Scientific Advisory Board (SAB) chaired by Dr. Carl Regillo, a distinguished retinal surgeon. The SAB includes acclaimed members from prestigious institutions like Mayo Clinic and Duke University. This board aims to guide EyePoint's management in advancing its ocular product pipeline, notably the Phase 1 DAVIO trial for EYP-1901, a potential treatment for wet age-related macular degeneration. The board's collective expertise is expected to enhance the company's scientific strategy and improve patient outcomes.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will host a conference call on August 4, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and recent business highlights. Investors can join the call by dialing (877)-312-7507 for domestic calls or (631)-813-4828 for international calls, using conference ID 1861354. The event will also be available via a live audio webcast on the company’s website. EyePoint is focused on innovative therapeutics for serious eye disorders and utilizes its proprietary Durasert® technology for extended drug delivery.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a nine-month extension of DEXYCU®'s pass-through payment status following a draft ruling by the Centers for Medicare and Medicaid Services (CMS). This extension, set to last until December 31, 2022, aids in the coverage of outpatient drugs during cataract surgeries, impacting approximately 60% of Medicare Part B patients. The final ruling from CMS is expected in November 2021. CEO Nancy Lurker expressed optimism about the extension, emphasizing its significance for DEXYCU's commercial strategy.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has reported positive safety results from its Phase 1 clinical trial of EYP-1901, aimed at treating wet age-related macular degeneration (wet AMD). The trial involved 17 patients and showed no serious adverse events after 30-day follow-ups. The company anticipates releasing interim efficacy results in Q4 2021 and plans to initiate trials for diabetic retinopathy and retinal vein occlusion. EYP-1901 utilizes proprietary Durasert® technology for sustained drug delivery, demonstrating the company's commitment to advancing eye disorder treatments.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that the American Medical Association accepted a new Category III CPT code (0X78T) for drug administration in the eye, effective January 1, 2022. This code provides a reimbursement pathway for DEXYCU, the first FDA-approved sustained-release intracameral steroid for postoperative inflammation treatment. The approval is seen as a significant step toward increased adoption of DEXYCU, enhancing its market presence and financial prospects.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced its inclusion in the small-cap Russell 2000® Index and the broader Russell 3000® Index, effective June 28, 2021. This addition reflects the company’s position among approximately 2,000 smaller companies based on market capitalization.
The Russell indexes are critical benchmarks for investment strategies, managing $10.6 trillion in assets. EyePoint focuses on therapeutics for serious eye disorders, leveraging its proprietary Durasert® technology and two commercial products, YUTIQ® and DEXYCU®.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will have CEO Nancy Lurker speak at the Jefferies Healthcare Conference on June 2, 2021, at 9:30 a.m. ET. The session will explore the company's commitment to developing therapies for serious eye disorders, including innovations like EYP-1901, a treatment for wet age-related macular degeneration. Attendees can access a live webcast and a 90-day archive via EyePoint's website. The company also markets YUTIQ and DEXYCU for eye disorder treatments.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced successful enrollment completion for its Phase 1 trial of EYP-1901, a potential twice-yearly treatment for wet age-related macular degeneration (wet AMD). The trial includes dose escalation for patients previously responsive to anti-VEGF therapies. Interim data is expected in Q4 2021. EYP-1901 employs EyePoint’s Durasert technology for sustained delivery, potentially improving treatment outcomes for patients. The company aims to explore additional applications for EYP-1901, including diabetic retinopathy.
FAQ
What is the current stock price of EyePoint Pharmaceuticals (EYPT)?
What is the market cap of EyePoint Pharmaceuticals (EYPT)?
What does EyePoint Pharmaceuticals, Inc. (EYPT) specialize in?
What is DURAVYU™?
Where is EyePoint Pharmaceuticals headquartered?
What are the key products in EyePoint's pipeline?
How did EyePoint Pharmaceuticals perform financially in 2023?
What is the Durasert® technology?
Has EyePoint Pharmaceuticals received FDA approval for any products?
What are the geographical operational footprints of EyePoint Pharmaceuticals?
What is EyePoint's strategy for future growth?
How does EyePoint Pharmaceuticals generate revenue?
